The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Midas Pharma GmbHEU/1/22/1673/001

Main Information

Trade NameRaniviso
Active SubstancesRanibizumab
Dosage FormSolution for injection
Licence HolderMidas Pharma GmbH
Licence NumberEU/1/22/1673/001

Group Information

ATC CodeS01LA04 ranibizumab


License statusAuthorised
Licence Issued25/08/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back